Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437866 | 0.91 | KDM4E (0.51) | KDM4EPOLBLMNAABL1PKM | |
| SCHEMBL23207522 | 0.84 | KDM4E (0.62) | KDM4EPOLBLMNAABL1PKM | |
| SCHEMBL30582921 | 0.82 | KDM4E (0.60) | KDM4EPOLBLMNAABL1PKM | |
| SCHEMBL16238574 | 0.82 | KDM4E (0.60) | KDM4EPOLBLMNAABL1PKM | |
| SCHEMBL1646635 | 0.81 | KDM4E (0.57) | KDM4EPOLBLMNAABL1L3MBTL1 | |
| SCHEMBL30776193 | 0.80 | MAPT (0.51) | KDM4EPOLBLMNAABL1L3MBTL1 | |
| SCHEMBL13519197 | 0.80 | HRH3 (0.40) | KDM4ELMNAPKMMAPTALDH1A1 | |
| SCHEMBL30582924 | 0.77 | KDM4E (0.55) | KDM4EPOLBLMNAABL1PKM | |
| SCHEMBL28666230 | 0.76 | MAPT (0.37) | KDM4ELMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL27925587 | 0.76 | GRIN2D (0.48) | KDM4EPOLBLMNAL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105153146-A | Novel 3-hydroxyisothiazole 1-oxide derivative | MOCHIDA PHARM CO LTD | 2015-12-16 | — | — | CN | disclosed |
| CN-103517898-B | Novel 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO.,LTD. (JP) | 2015-09-30 | — | — | CN | disclosed |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-8765752-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2703394-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2703393-A1 | CYCLIC AMIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| CN-103517898-A | Novel 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARM CO LTD | 2014-01-15 | — | — | CN | disclosed |
| US-8629102-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8557766-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | KDM4E 2196/4885POLB 4232/4885LMNA 3943/4885 |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | KDM4E 2211/4885POLB 4161/4885LMNA 4092/4885 |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | KDM4E 3664/4885POLB 4708/4885LMNA 4376/4885 |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | KDM4E 3664/4885POLB 4708/4885LMNA 4376/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | KDM4E 2989/4885POLB 4263/4885LMNA 3503/4885 |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | GPR119, GPR27, GPR65 | KDM4E 3604/4885POLB 4734/4885LMNA 4370/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | KDM4E 2927/4885POLB 4340/4885LMNA 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.